J F Bonneville,J Potorac,A Beckers
J F Bonneville
Aggresssive pituitary tumors are defined as radiologically invasive, exhibiting a rapid growth and a poor response to the medical and surgical treatment options. The role of magnetic resonance imaging (MRI) is fundamental to assess tumor ag...
Acute assessment of subjective appetite and implicated hormones after a hypnosis-induced hallucinated meal: a randomized cross-over pilot trial [0.03%]
幻觉餐对主观饥饿感和激素影响的急性评估：一项随机交叉试验试点研究
Iolanda Cioffi,Roberto Gambino,Rosalba Rosato et al.
Iolanda Cioffi et al.
The use of hypnosis can generate hallucinatory phenomena, which ranged from vivid/auditory imagery to fully developed "hallucinations" in selected people. The aim of this pilot trial was investigating the acute effects of a hypnosis-induced...
Randomized Controlled Trial
Reviews in endocrine & metabolic disorders. 2020 Sep;21(3):411-420. DOI:10.1007/s11154-020-09559-4 2020
Targeted systemic and peptide radio-ligand therapy for aggressive pituitary tumors and carcinomas [0.03%]
生长激素型肢端肥大症和垂体癌的靶向系统及肽放射配体治疗
Stephan Petersenn,Anthony P Heaney
Stephan Petersenn
Aggressive pituitary tumors comprise a rare but challenging subset of pituitary tumors. A major issue currently is the absence of a holistic definition that reliably identifies these tumors in a prospective manner. Although comprehensive ev...
Zinc-alpha2-glycoprotein, dysglycaemia and insulin resistance: a systematic review and meta-analysis [0.03%]
锌-α2-糖蛋白与糖代谢异常和胰岛素抵抗的关系：系统综述和meta分析
Harriet M Pearsey,Joseph Henson,Jack A Sargeant et al.
Harriet M Pearsey et al.
To systematically review the current literature investigating associations between zinc-alpha2-glycoprotein (ZAG) and dysglycaemia (including type 2 diabetes (T2DM), poly-cystic-ovary syndrome (PCOS), pre-diabetes or insulin resistance). Th...
Olaf M Dekkers,Niki Karavitaki,Alberto M Pereira
Olaf M Dekkers
Pituitary tumors are not rare if prevalence rates from autopsy or radiological series are considered; approximately 0.5% of all pituitary adenomas will come to medical attention. Less than 0.1% of these pituitary adenomas will become malign...
Hyperinsulinemic hypoglycemia in children and adolescents: Recent advances in understanding of pathophysiology and management [0.03%]
儿童和青少年高胰岛素血症性低血糖症：病理生理及治疗新进展
Maria Gϋemes,Sofia Asim Rahman,Ritika R Kapoor et al.
Maria Gϋemes et al.
Hyperinsulinemic hypoglycemia (HH) is characterized by unregulated insulin release, leading to persistently low blood glucose concentrations with lack of alternative fuels, which increases the risk of neurological damage in these patients. ...
Consensus statement from 2nd International Conference on Controversies in Vitamin D [0.03%]
第二届维生素D国际会议共识声明
A Giustina,R A Adler,N Binkley et al.
A Giustina et al.
The 2nd International Conference on Controversies in Vitamin D was held in Monteriggioni (Siena), Italy, September 11-14, 2018. The aim of this meeting was to address ongoing controversies and timely topics in vitamin D research, to review ...
Serotonin pathway in carcinoid syndrome: Clinical, diagnostic, prognostic and therapeutic implications [0.03%]
血清素通路在类癌综合征中的临床、诊断、预后和治疗意义
Giuseppe Fanciulli,Rosaria M Ruggeri,Erika Grossrubatscher et al.
Giuseppe Fanciulli et al.
Carcinoid syndrome represents the most common functional syndrome that affects patients with neuroendocrine neoplasms. Its clinical presentation is really heterogeneous, ranging from mild and often misdiagnosed symptoms to severe manifestat...
Temozolomide therapy for aggressive pituitary tumours - current understanding and future perspectives [0.03%]
替莫唑胺治疗侵袭性垂体肿瘤的现状和未来展望
Pia Burman,Lydia Lamb,Ann McCormack
Pia Burman
The use of temozolomide (TMZ) for the management of aggressive pituitary tumours (APT) has revolutionised clinical practice in this field with significantly improved clinical outcomes and long-term survival. Its use is now well established ...
Type 2 diabetes - unmet need, unresolved pathogenesis, mTORC1-centric paradigm [0.03%]
2型糖尿病：未满足的需求、未解决的发病机制和以mTORC1为中心的研究范式
Jacob Bar-Tana
Jacob Bar-Tana
The current paradigm of type 2 diabetes (T2D) is gluco-centric, being exclusively categorized by glycemic characteristics. The gluco-centric paradigm views hyperglycemia as the primary target, being driven by resistance to insulin combined ...